AlzeCure Pharma (ALZCUR) Q4 2024 earnings summary

Executive summary

• Focused on developing small-molecule drugs for CNS diseases, especially Alzheimer's and pain, with three main platforms: NeuroRestore, Alzstatin, and Painless.

• Advanced lead Alzheimer's candidate ACD856 toward Phase II, with new preclinical data showing neuroprotective and anti-inflammatory effects.

• Alzstatin's ACD680 selected for further development, expected to have strong patent protection and "Best-in-Class" potential.

• Painless platform's ACD440 and TrkA-NAM (ACD137) showed promising clinical and preclinical results for neuropathic and osteoarthritis pain.

• Awarded €2.5 million EIC Accelerator grant in February 2025 to support Phase II trial of ACD856.

Financial highlights

• Net sales were SEK 0 thousand for both Q4 and full year 2024, unchanged from prior year.

• Q4 2024 loss: SEK -9,330 thousand (improved from -9,756); full year loss: SEK -35,234 thousand (improved from -37,167).

• EPS, basic: SEK -0.11 for Q4 (vs. -0.16); SEK -0.46 for full year (vs. -0.60).

• Cash and cash equivalents at year-end: SEK 31,498 thousand (up from 29,100).

• Cash flow from operating activities: SEK -7,565 thousand in Q4; SEK -35,123 thousand for the year.

Outlook and guidance

• Preparing ACD856 for Phase II clinical studies in Alzheimer's, supported by EIC grant.

• Alzstatin's ACD680 to enter clinical trials, with extended patent life and exclusivity.

• Continued business development to seek out-licensing or partnerships for pipeline assets.

• Financing risk remains high; available funds not sufficient for all planned activities over next 12 months.